TY  - JOUR
TI  - First year real life experience with tenofovir alafenamide  fumarate: The pythagorean cohort
AB  - Background and Aim: In chronic hepatitis B infection, antiviral therapy  significantly reduces the incidence of complications. This study aimed to  present real-life 12-month effectiveness and safety data for TAF. Materials and Methods: This Pythagoras Retrospective Cohort Study in cluded patients from 14 centers in Turkiye. The study presents 12-month  results of 480 patients treated with TAF as initial therapy or after switching  from another antiviral drug. Results: The study shows treatment of about 78.1% patients with at least  one antiviral agent (90.6% tenofovir disoproxil [TDF]). The rate of unde tectable HBV DNA increased in both treatment-experienced and naive pa tients. In TDF-experienced patients, the rate of alanine transaminase (ALT)  normalization increased slightly (1.6%) within 12 months, but the change was not statistically significant (p=0.766). Younger age, low albumin, and  high body mass index and cholesterol were identified as risk factors for  abnormal ALT after 12 months, but no linear relationship was detected. In  TDF-experienced patients, renal and bone function indicators showed sig nificant improvement three months after the transition to TAF and remained  stable for 12 months.  Conclusion: Real-life data demonstrated effective virological and bio chemical responses with TAF therapy. After switching to TAF treat ment, gains in kidney and bone functions were achieved in the early  period.
AU  - İNAN, DİLARA
AU  - DEMİR, YAKUP
AU  - Karaşahin, Ömer
AU  - Harputluoglu, Murat
AU  - NAZİK, SELÇUK
AU  - BAYINDIR, Yasar
AU  - Ören, Merve
AU  - Akdemir Kalkan, İrem
AU  - Kandemir, Özlem
AU  - Kaya, Safak
AU  - CELEN, MUSTAFA
AU  - özer balın, şafak
AU  - komur, suheyla
AU  - TASOVA, YESIM
AU  - Yildiz, Yesim
AU  - Sarıgül, Figen
AU  - Dal, Tuba
AU  - ALTUNIŞIK TOPLU, SİBEL
AU  - mete, ayşe özlem
AU  - ESMER, FATİH
AU  - TUNÇ, NURETTIN
AU  - akgul, fethiye
AU  - aktar, fesih
AU  - ayhan, merve
DO  - 10.14744/hf.2022.2022.0043
PY  - 2023
JO  - Hepatology forum
VL  - 4
IS  - 2
SN  - 1307-5888
SP  - 61
EP  - 68
DB  - TRDizin
UR  - http://search/yayin/detay/1178904
ER  -